Immatics Past Earnings Performance
Past criteria checks 0/6
Immatics has been growing earnings at an average annual rate of 15.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 26.7% per year.
Key information
15.6%
Earnings growth rate
30.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 26.7% |
| Return on equity | -14.6% |
| Net Margin | -48.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Immatics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 116 | -56 | 43 | 21 |
| 30 Jun 24 | 71 | -74 | 41 | -2 |
| 31 Mar 24 | 74 | -80 | 40 | 0 |
| 31 Dec 23 | 54 | -97 | 38 | 0 |
| 30 Sep 23 | 76 | -84 | 38 | 0 |
| 30 Jun 23 | 85 | -79 | 37 | 7 |
| 31 Mar 23 | 80 | -68 | 36 | 0 |
| 31 Dec 22 | 173 | 38 | 36 | 0 |
| 30 Sep 22 | 151 | 34 | 35 | 0 |
| 30 Jun 22 | 142 | 28 | 35 | 0 |
| 31 Mar 22 | 130 | 15 | 35 | 0 |
| 31 Dec 21 | 35 | -93 | 34 | 0 |
| 30 Sep 21 | 28 | -95 | 34 | 0 |
| 30 Jun 21 | 30 | -231 | 35 | 0 |
| 31 Mar 21 | 32 | -226 | 36 | 0 |
| 31 Dec 20 | 31 | -211 | 34 | 0 |
| 30 Sep 20 | 26 | -208 | 30 | 0 |
| 30 Jun 20 | 23 | -49 | 24 | 0 |
| 31 Mar 20 | 22 | -34 | 16 | 0 |
| 31 Dec 19 | 18 | -32 | 12 | 0 |
| 31 Dec 18 | 4 | -31 | 8 | 0 |
Quality Earnings: 4A3 is currently unprofitable.
Growing Profit Margin: 4A3 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4A3 is unprofitable, but has reduced losses over the past 5 years at a rate of 15.6% per year.
Accelerating Growth: Unable to compare 4A3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4A3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 4A3 has a negative Return on Equity (-14.59%), as it is currently unprofitable.